NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Receives Average Recommendation of “Hold” from Analysts

Posted by Geri Gentry on Jul 30th, 2026

Shares of NeuroOne Medical Technologies Corporation (NASDAQ:NMTC – Get Free Report) have received an average rating of “Hold” from the five ratings firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $11.6667.

NMTC has been the subject of a number of recent analyst reports. Weiss Ratings upgraded shares of NeuroOne Medical Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday. LADENBURG THALM/SH SH upped their price target on shares of NeuroOne Medical Technologies from $1.60 to $8.00 and gave the company a “buy” rating in a research note on Wednesday, May 13th.

View Our Latest Report on NMTC

NeuroOne Medical Technologies Stock Performance

Shares of NASDAQ NMTC opened at $1.65 on Thursday. The company has a market cap of $14.36 million, a PE ratio of -1.94 and a beta of 0.54. The business has a 50-day simple moving average of $3.01 and a two-hundred day simple moving average of $4.08. NeuroOne Medical Technologies has a fifty-two week low of $1.61 and a fifty-two week high of $6.96.

NeuroOne Medical Technologies (NASDAQ:NMTC – Get Free Report) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.02). NeuroOne Medical Technologies had a negative net margin of 68.35% and a negative return on equity of 99.43%. The company had revenue of $1.86 million for the quarter, compared to analyst estimates of $2.58 million. On average, sell-side analysts predict that NeuroOne Medical Technologies will post -0.36 earnings per share for the current fiscal year.

Insider Buying and Selling at NeuroOne Medical Technologies

In other news, Director Mark Christianson sold 10,000 shares of the business’s stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $3.18, for a total transaction of $31,800.00. Following the sale, the director directly owned 20,692 shares of the company’s stock, valued at $65,800.56. The trade was a 32.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 11.80% of the stock is owned by company insiders.

Institutional Trading of NeuroOne Medical Technologies

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NMTC. Legato Capital Management LLC purchased a new stake in NeuroOne Medical Technologies during the 4th quarter valued at about $34,000. Squarepoint Ops LLC purchased a new position in shares of NeuroOne Medical Technologies in the fourth quarter worth about $36,000. Susquehanna International Group LLP purchased a new position in shares of NeuroOne Medical Technologies in the third quarter worth about $47,000. XTX Topco Ltd acquired a new stake in shares of NeuroOne Medical Technologies during the second quarter worth about $51,000. Finally, Goldman Sachs Group Inc. acquired a new stake in shares of NeuroOne Medical Technologies during the first quarter worth about $84,000. Institutional investors and hedge funds own 16.07% of the company’s stock.

NeuroOne Medical Technologies Company Profile

(Get Free Report)

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.